HIV Infections Clinical Trial
— IYG-AI/ANOfficial title:
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
This study will evaluate the effect of an American Indian/Alaska Native (AI/AN) adaptation of the It's Your Game…Keep It Real (IYG) intervention, relative to a comparison condition on sexual behavior outcomes and psychosocial variables for middle school aged youth (12 - 14 years old). The original IYG program was designed for students in Houston middle schools to help students delay sexual initiation and if sexually active, use condoms and contraception. The present study will adapt the existing IYG program for an AI/AN youth cohort; the original IYG curriculum will be transferred into a web-based format and modified to incorporate additional culturally-relevant components. The primary hypothesis to be tested is: (1) students who receive the web-based curriculum will delay sexual activity relative to those who receive standard care. The major dependent variable is the proportion of students initiating sexual activity. Secondary hypotheses will examine the effect of the web-based curriculum on specific types of sex and psychosocial variables related to sexual risk-taking behavior. This project will also examine the effect of the intervention on the proportion of students who are sexually active, number of times students engage in unprotected sexual intercourse, and students' number of sexual partners.
Status | Completed |
Enrollment | 574 |
Est. completion date | January 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 12 Years to 14 Years |
Eligibility |
Inclusion Criteria: - American Indian or Alaska Native descent and/or tribal affiliation - Youth ages 12-14 attending regular classes in regional middle schools or youth attending after-school programs and/or Boys and Girls Clubs - English-speaking Exclusion Criteria: - Youth who are not of American Indian or Alaska Native descent - Any physical or mental condition that would inhibit the ability to complete surveys and use computer programs, such as cognitive impairment, motor disorders (e.g. quadriplegia), learning difficulties or psychiatric/behavioral problems (e.g. autism, attention deficit disorder) - Students will be informed that the surveys and intervention materials will only be available in English and will be asked to consider their comfort level with participating in the study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Alaska Native Tribal Health Consortium | Anchorage | Alaska |
United States | University of Texas Health Science Center, Houston | Houston | Texas |
United States | Inter Tribal Council of Arizona, Inc. | Phoenix | Arizona |
United States | Northwest Portland Area Indian Health Board | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston | Alaska Native Tribal Health Consortium, Inter Tribal Council of Arizona, Northwest Portland Area Indian Health Board |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Delay onset of sexual activity | delay onset of vaginal, oral or anal sex | baseline | No |
Primary | Delay onset of sexual activity | delay onset of vaginal, oral or anal sex | 5-months | No |
Primary | Delay onset of sexual activity | delay onset of vaginal, oral or anal sex | 16-months | No |
Secondary | Reduce alcohol/drug use | baseline | No | |
Secondary | Reduce instances of sexual activity | baseline | No | |
Secondary | Decrease the number of sexual partners | baseline | No | |
Secondary | Condom use during sexual activity | baseline | No | |
Secondary | Contraceptive use while sexually active | baseline | No | |
Secondary | Prevalence of sexually transmitted infections | baseline | No | |
Secondary | Increase sexual knowledge | baseline | No | |
Secondary | Changes in sexual beliefs | baseline | No | |
Secondary | Changes in attitudes toward sexual activity | baseline | No | |
Secondary | Changes in perception of sexual beliefs among peers | baseline | No | |
Secondary | Increased self-efficacy for refusal skills | baseline | No | |
Secondary | Increased self-efficacy for condom use | baseline | No | |
Secondary | Increased avoidance of risky situations | baseline | No | |
Secondary | Changes in perceived norms about sexual activity | baseline | No | |
Secondary | Changes in reasons for or against having sex | baseline | No | |
Secondary | Changes in intentions to have/abstain from sex | baseline | No | |
Secondary | Reduce alcohol/drug use | 5-months | No | |
Secondary | Reduce alcohol/drug use | 16-months | No | |
Secondary | Reduce instances of sexual activity | 5-months | No | |
Secondary | Reduce instances of sexual activity | 16-months | No | |
Secondary | Decrease the number of sexual partners | 5-months | No | |
Secondary | Decrease the number of sexual partners | 16-months | No | |
Secondary | Condom use during sexual activity | 5-months | No | |
Secondary | Condom use during sexual activity | 16-months | No | |
Secondary | Contraceptive use while sexually active | 5-months | No | |
Secondary | Prevalence of sexually transmitted infections | 5-months | No | |
Secondary | Prevalence of sexually transmitted infections | 16-months | No | |
Secondary | Increase sexual knowledge | 5-months | No | |
Secondary | Increase sexual knowledge | 16-months | No | |
Secondary | Changes in sexual beliefs | 5-months | No | |
Secondary | Changes in sexual beliefs | 16-months | No | |
Secondary | Changes in attitudes toward sexual activity | 5-months | No | |
Secondary | Changes in attitudes toward sexual activity | 16-months | No | |
Secondary | Changes in perception of sexual beliefs among peers | 5-months | No | |
Secondary | Changes in perception of sexual beliefs among peers | 16-months | No | |
Secondary | Increased self-efficacy for refusal skills | 5-months | No | |
Secondary | Increased self-efficacy for refusal skills | 16-months | No | |
Secondary | Increased self-efficacy for condom use | 5-months | No | |
Secondary | Increased self-efficacy for condom use | 16-months | No | |
Secondary | Increased avoidance of risky situations | 5-months | No | |
Secondary | Increased avoidance of risky situations | 16-months | No | |
Secondary | Changes in perceived norms about sexual activity | 5-months | No | |
Secondary | Changes in perceived norms about sexual activity | 16-months | No | |
Secondary | Changes in reasons for or against having sex | 5-months | No | |
Secondary | Changes in reasons for or against having sex | 16-months | No | |
Secondary | Changes in intentions to have/abstain from sex | 5-months | No | |
Secondary | Changes in intentions to have/abstain from sex | 16-months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |